Crofelemer

N/A

Report date: 2025/09/17 11:04:15
NMEFirst In Class

Base Information

Drug NameCrofelemer
Drug Alias NameMytesiVirendFulyzaqProvirCRO-ID +[10] 
ClassificationNatural product/Extract > Plants extractSmall molecules > Heterocyclic drugs
Mechanisms of ActionChloride channel blockersCystic fibrosis transmembrane conductance regulator inhibitors
TargetsChloride channelCystic fibrosis transmembrane conductance regulator
Therapy Area/IndicationsSolid tumoursMicrovillus inclusion diseaseDiarrhea +[13] 
Global Approved IndicationsDiarrhea
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2012/12/31
Country/TerritoryUnited StatesTaiwanSerbia +[9] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesJaguar HealthNapo Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesNapo Therapeutics SPANapo EU SPANapo Pharmaceuticals Inc
Inactive CompaniesShaman Pharmaceuticals IncBausch Health Americas Inc
Active IndicationsSolid tumoursMicrovillus inclusion diseaseDiarrhea +[8] 
Inactive IndicationsCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesIrritable Bowel SyndromeColonic Diseases +[5] 

Other Information

ATC CodeA07XA06
Related LinksWikipediaDrugBankKEGG